Breast Care Center, Professor of Surgery & Medical Oncology, Jefferson Medical College, Philadelphia, PA 19107, USA.
Breast J. 2012 Jul-Aug;18(4):303-11. doi: 10.1111/j.1524-4741.2012.01264.x.
A consensus conference was held in order to provide guidelines for the use of adjuvant therapy in patients with Stage I carcinoma of the breast, using traditional information, such as tumor size, microscopic character, Nottingham index, patient age and co-morbidities, but also incorporating steroid hormone and Her-2-neu data as well as other immunohistochemical markers. The role of the genetic analysis of breast cancer and proprietary gene prognostic signatures was discussed, along with the molecular profiling of breast cancers into several groups that may predict prognosis. These molecular data are not currently sufficiently mature to make them part of decision making algorithms of recommendations for the treatment of individual patients.
为了提供关于辅助治疗在 I 期乳腺癌患者中的应用指南，我们召开了一次共识会议。这些指南采用了传统信息，如肿瘤大小、显微镜特征、诺丁汉指数、患者年龄和合并症等，同时还纳入了甾体激素和 Her-2-neu 数据以及其他免疫组织化学标志物。还讨论了乳腺癌的基因分析和专有基因预后标志物的作用，以及将乳腺癌分子谱分为几个可能预测预后的组。这些分子数据目前还不够成熟，无法将其纳入针对个体患者治疗建议的决策算法中。
